New developments in the era of viral hepatitis vaccines

References (108)

1. McMahon BJ. Epidemiology and natural history of hepatitis
2. B. Semin Liver Dis 2005; 25 Suppl 1:3.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden
4. treatment, and current and emerging prevention and control
5. measures. J Viral Hepat 2004; 11:97.
6. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B
7. vaccine: demonstration of efficacy in a controlled clinical trial
8. in a high-risk population in the United States. N Eng J Med
9. 833–4.
10. McAleer WJ, Buynack EB, Maigetter RZ, Wampler DE
11. Miller WJ, Hilleman MR. Human hepatitis B vaccine from
12. recombinant yeast. Nature 1984;307:178–80.
13. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson
14. B, Maddrey WC, US Hepacare Study Group, Adult hepatitis
15. B vaccination using a novel triple antigen recombinant
16. vaccine. Hepatology 2001;34:372.
17. Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibodyresponse
18. to three recombinant hepatitis B vaccines
19. comparative evaluation of multicenter travel-clinic based
20. experience. Vaccine 2001; 19:2055-60.
21. Blatter M, Joines R, Resinger K, et al. An open, randomized
22. controlled study to evaluate the safety and immunogenicity
23. of SmithKline Beecham Biologicals’ combined hepatitis A/
24. hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In
25. Program and abstracts of the 39th Interscience Conference
26. on Antimicrobial Agents and Chemotherapy (San Francisco)
27. American Society for Microbiology, Washington, DC
28. Abraham B, Parenti D. Antibody production in response
29. to hepatitis B surface antigen in a combination hepatitis A/
30. hepatitis B vaccine. J Infect Dis 2000; 182:1005-6.
31. Hadler SC, Francis DP, Maynard JE, et al. Long-term
32. immunogenicity and efficacy of hepatitis B vaccine in
33. homosexual men. N Engl J Med 1986; 315:209-14.
34. Poland GA. Hepatitis B immunization in health care workers.
35. Dealing with vaccine nonresponse. Am J Prev Med 1998
36. Propst T, Propst A, Lhotta K, et al. Reinforced intradermal
37. hepatitis B vaccination in hemodialysis patients is superior
38. in antibody response to intramuscular or subcutaneous
39. vaccination. Am J Kidney Dis 1998; 32:1041-5.
40. Peces R, de la Torre M, Alcázar R, Urra JM. Prospective
41. analysis of the factors influencing the antibody response to
42. hepatitis B vaccine in hemodialysis patients. Am J Kidney
43. Dis 1997; 29:239-45.
44. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic
45. prediction of nonresponse to hepatitis B vaccine. N Engl J
46. Med 1989; 321:708-12.
47. Makidon PE, Bielinska AU, Nigavekar SS, et al. Preclinical
48. evaluation of a novel nanoemulsion-based hepatitis
49. B mucosal vaccine. PLoS One 2008; 3:e2954. doi: 10.1371/
50. journal.pone.0002954
51. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and
52. immunogenicity of two doses of investigational hepatitis B virus
53. surface antigen co-administered with an immunostimulatory
54. phosphorothioate oligodeoxyribonucleotide and three doses
55. of a licensed hepatitis B vaccine in healthy adults 18-55
56. years of age. Vaccine 2012; 30:2556-63. doi: 10.1016/j.
57. vaccine.2012.01.087
58. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of
59. safety and enhanced seroprotection against hepatitis B with
60. investigational HBsAg-1018 ISS vaccine compared to a
61. licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. doi
62. j.vaccine.2012.02.001
63. Singh M, Li XM, McGee JP, et al. Controlled release
64. microparticles as a single dose hepatitis B vaccine: evaluation
65. of immunogenicity in mice. Vaccine 1997; 15:475-81.
66. Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular
67. and humoral immune responses induced by intradermal or
68. intramuscular vaccination with the major hepatitis B surface
69. antigen. Hepatology 2000; 31:521-7.
70. Rault R, Freed B, Nespor S, Bender F. Efficacy of different
71. hepatitis B vaccination strategies in patients receiving
72. hemodialysis. ASAIO J 1995; 41:M717.
73. Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis
74. intradermal vs. intramuscular vaccination against hepatitis
75. B virus in patients with chronic kidney disease. Aliment
76. Pharmacol Ther 2006; 24:497-506.
77. Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in
78. haemodialysis patients. Lancet 1989; 1:1264.
79. Jungers P, Devillier P, Salomon H, et al. Randomised
80. placebo-controlled trial of recombinant interleukin-2 in
81. chronic uraemic patients who are non-responders to hepatitis
82. B vaccine. Lancet 1994; 344:856.
83. Thoelen S, Van Damme P, Mathei C, et al. Safety and
84. immunogenicity of a hepatitis B vaccine formulated with a
85. novel adjuvant system. Vaccine 1998; 16:708.
86. Traquina P, Morandi M, Contorni M, Van Nest G. MF59
87. adjuvant enhances the antibody response to recombinant
88. hepatitis B surface antigen vaccine in primates. J Infect Dis
89. Jacques P, Moens G, Desombere I, et al. The immunogenicity
90. and reactogenicity profile of a candidate hepatitis B vaccine
91. in an adult vaccine non-responder population. Vaccine 2002
92. Sprengers D, Janssen HLA. Immunomodulatory therapy for
93. chronic hepatitis B virus infection. Fundam Clin Pharmacol
94. 17–26
95. Tozun N, Ozdogan OC, Cakaloglu Y, et al. A nationwide
96. prevalance study and risk factors for hepatitis A, B, C and
97. D infections in Turkey. Hepatology Volume 2010; 52
98. (Supplement S1): 697A.
99. Houghton M. Prospects for prophylactic and therapeutic
100. vaccines against the hepatitis C viruses. Immunol Rev 2011
101. 99–108.
102. Frey SE, Houghton M, Coates S, et al. Safety and
103. immunogenicity of HCV E1E2 vaccine adjuvanted with
104. MF59 administered to healthy adults. Vaccine 2010; 28
105. Law LMJ, Landi A, Magee WC, Tyrrell DL, Houghton
106. H. Progress towards a hepatitis C virus vaccine. Emerging
107. Microbes and Infections 2013;2:e79. doi:10.1038/
108. emi.2013.79; published online 20 November 2013